TNFRSF4 and neoplasm: A number of trials with OX40 agonists are ongoing in a range of tumor types, evaluating the therapeutic potential of single agents or in combination therapy with other agents.24 25 34 35 In the current study, although there were no safety concerns with INCAGN01949 monotherapy in patients with metastatic or advanced solid tumors, the study was discontinued owing to lack of anticipated pharmacodynamic effects on T cells in peripheral blood and post-therapy tumor biopsies, and lack of clinical activity.